Juneja D, Nasa P, Jain R, Singh O. Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports. World J Diabetes 2023; 14(8): 1314-1322 [PMID: 37664476 DOI: 10.4239/wjd.v14.i8.1314]
Corresponding Author of This Article
Deven Juneja, FCCP, MD, Director, Institute of Critical Care Medicine, Max Super Speciality Hospital, Saket, 1, Press Enclave Road, New Delhi 110017, India. devenjuneja@gmail.com
Research Domain of This Article
Critical Care Medicine
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Aug 15, 2023; 14(8): 1314-1322 Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1314
Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports
Deven Juneja, Prashant Nasa, Ravi Jain, Omender Singh
Deven Juneja, Omender Singh, Institute of Critical Care Medicine, Max Super Speciality Hospital, Saket, New Delhi 110017, India
Prashant Nasa, Department of Critical Care Medicine, NMC Specialty Hospital, Dubai 7832, United Arab Emirates
Prashant Nasa, Department of Internal Medicine, College of Medicine and Health Sciences, Al Ain 15551, Abu Dhabi, United Arab Emirates
Ravi Jain, Department of Critical Care Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur 302022, Rajasthan, India
Author contributions: Juneja D acquisition of data, analysis and interpretation of data, drafting the article, final approval; Nasa P acquisition of data, analysis and interpretation of data, drafting the article, final approval; Jain R interpretation of data, revising the article, final approval; Singh O designing the study, drafting the article, final approval.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Deven Juneja, FCCP, MD, Director, Institute of Critical Care Medicine, Max Super Speciality Hospital, Saket, 1, Press Enclave Road, New Delhi 110017, India. devenjuneja@gmail.com
Received: April 27, 2023 Peer-review started: April 27, 2023 First decision: May 19, 2023 Revised: May 20, 2023 Accepted: June 19, 2023 Article in press: June 19, 2023 Published online: August 15, 2023
Core Tip
Core Tip: Sodium-glucose cotransporter-2 inhibitors are a newer class of oral hypoglycemic drugs commonly prescribed for managing patients with diabetes mellitus. Even though these drugs are effective in controlling blood glucose and have favorable cardiac effects, they may rarely lead to the development of euglycemic diabetic ketoacidosis (EDKA), which may complicate the disease course of these patients. Certain risk factors, such as severe acute illness and major surgery, may predispose these patients to develop EDKA. The signs and symptoms of EDKA are similar to classic symptoms of diabetic ketoacidosis, but these patients have normal blood glucose levels, making the diagnosis difficult. Hence, a higher index of suspicion is warranted in such patients, as delay in diagnosis may lead to higher morbidity and mortality.
